{
    "clinical_study": {
        "@rank": "43729", 
        "acronym": "hGH", 
        "arm_group": [
            {
                "arm_group_label": "Dose level 1 of CJ-40002", 
                "arm_group_type": "Experimental", 
                "description": "Single dose\n8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
            }, 
            {
                "arm_group_label": "Dose level 2 of CJ-40002", 
                "arm_group_type": "Experimental", 
                "description": "Single dose\n8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
            }, 
            {
                "arm_group_label": "Dose level 3 of CJ-40002", 
                "arm_group_type": "Experimental", 
                "description": "Single dose\n8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
            }, 
            {
                "arm_group_label": "Dose level 4 of CJ-40002", 
                "arm_group_type": "Experimental", 
                "description": "Single dose\n8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
            }, 
            {
                "arm_group_label": "Dose level 5 of CJ-40002", 
                "arm_group_type": "Experimental", 
                "description": "Single dose\n8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are:\n\n        -  To evaluate the safety and tolerability of CJ-40002 after single SC injection in\n           healthy male volunteers.\n\n        -  To evaluate the PK of CJ-40002 after single SC injection in healthy male volunteers.\n\n        -  To evaluate the PD of CJ-40002 after single SC injection in healthy male volunteers.\n\n        -  To evaluate the ADA of CJ-40002 after single SC injection in healthy male volunteers."
        }, 
        "brief_title": "Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers in the age between 19 and 45 years old (inclusive)\n\n          -  Body mass index (BMI) in the range of 18.5 to 25 kg/m2 and weighing at least 55 kg\n\n          -  Subject who have voluntarily agreed to participate in the trial and signed the\n             written informed consent form, after having listened to the purpose, method, and\n             effect of the clinical trial\n\n        Exclusion Criteria:\n\n          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,\n             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric,\n             musculoskeletal or cardiovascular disease or any other condition\n\n          -  History of allergy or sensitivity to any drug\n\n          -  Subject with the following clinically significant laboratory abnormalities:\n\n               -  AST or ALT > 1.25 x Upper Limit Normal (ULN)\n\n               -  Total bilirubin > 1.5 x Upper Limit Normal (ULN)\n\n               -  CPK > 1.5 x Upper Limit Normal (ULN)\n\n               -  eGFR < 60 mL/min/1.73 m2\n\n          -  Systolic blood pressure outside the range of 90 to 150 mmHg or diastolic blood\n             pressure outside the range of 50 to 100 mmHg\n\n          -  History of drug abuse\n\n          -  History of caffeine, alcohol, smoking abuse\n\n          -  Participation in any clinical investigation within 60days prior to study medication\n             dosing\n\n          -  Subjects with whole blood donation within 60days, component blood donation within\n             30days prior to study medication dosing\n\n          -  Positive test results for HBs Ab, HCV Ab, HIV test\n\n          -  Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146625", 
            "org_study_id": "CJ_HGH_101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose level 1 of CJ-40002", 
                "Dose level 2 of CJ-40002", 
                "Dose level 3 of CJ-40002", 
                "Dose level 4 of CJ-40002", 
                "Dose level 5 of CJ-40002"
            ], 
            "intervention_name": "CJ-40002", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "number_of_arms": "5", 
        "official_title": "A Dose-block Randomized, Single-blind, Placebo-controlled, Single-dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CJ-40002 After Subcutaneous Injection in Healthy Adult Male Volunteers", 
        "overall_contact": {
            "email": "kssong1212@cj.net", 
            "last_name": "Geun Seog Song, PhD", 
            "phone": "82-2-6740-2440"
        }, 
        "overall_contact_backup": {
            "email": "keunji@cj.net", 
            "last_name": "Eun Ji Kim", 
            "phone": "82-2-6740-2443"
        }, 
        "overall_official": {
            "affiliation": "Yonsei University College of Medicine, Seoul, Korea", 
            "last_name": "Min Soo Park, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: AUC, Cmax", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Safety and Tolerability (AE's, vital signs, ECG, laboratory tests, local reaction)", 
                "safety_issue": "Yes", 
                "time_frame": "29 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146625"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Tmax, T1/2, CL/F, Vd", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Pharmacodynamics: Serum IGF-1, free IGF-1, IGFBP-3, GHBP", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Formation of anti-drug antibodies", 
                "safety_issue": "No", 
                "time_frame": "29 days"
            }
        ], 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}